Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86
MBX Biosciences, Inc.
MBX Biosciences, Inc. MBX | 0.00 |
Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:
MBX) with a Market Outperform and raises the price target from $76 to $86.
